Literature DB >> 22986524

EZH2 promotes a bi-lineage identity in basal-like breast cancer cells.

R Z Granit1, Y Gabai, T Hadar, Y Karamansha, L Liberman, I Waldhorn, I Gat-Viks, A Regev, B Maly, M Darash-Yahana, T Peretz, I Ben-Porath.   

Abstract

The mechanisms regulating breast cancer differentiation state are poorly understood. Of particular interest are molecular regulators controlling the highly aggressive and poorly differentiated traits of basal-like breast carcinomas. Here we show that the Polycomb factor EZH2 maintains the differentiation state of basal-like breast cancer cells, and promotes the expression of progenitor associated and basal-lineage genes. Specifically, EZH2 regulates the composition of basal-like breast cancer cell populations by promoting a ‘bi-lineage’ differentiation state, in which cells co-express basal- and luminal-lineage markers. We show that human basal-like breast cancers contain a subpopulation of bi-lineage cells, and that EZH2-deficient cells give rise to tumors with a decreased proportion of such cells. Bi-lineage cells express genes that are active in normal luminal progenitors, and possess increased colony-formation capacity, consistent with a primitive differentiation state. We found that GATA3, a driver of luminal differentiation, performs a function opposite to EZH2, acting to suppress bi-lineage identity and luminal-progenitor gene expression. GATA3 levels increase upon EZH2 silencing, mediating a decrease in bi-lineage cell numbers. Our findings reveal a novel role for EZH2 in controlling basal-like breast cancer differentiation state and intra-tumoral cell composition.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22986524     DOI: 10.1038/onc.2012.390

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  19 in total

1.  LncRNA FENDRR represses proliferation, migration and invasion through suppression of survivin in cholangiocarcinoma cells.

Authors:  Xinglei Qin; Min Lu; Yajun Zhou; Gang Li; Zhaoyang Liu
Journal:  Cell Cycle       Date:  2019-04-14       Impact factor: 4.534

2.  The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers.

Authors:  Woo Kyun Bae; Kyung Hyun Yoo; Ji Shin Lee; Young Kim; Ik-Joo Chung; Min Ho Park; Jung Han Yoon; Priscilla A Furth; Lothar Hennighausen
Journal:  Mol Carcinog       Date:  2014-07-07       Impact factor: 4.784

3.  Polyploid giant cancer cells, EZH2 and Myc upregulation in mammary epithelial cells infected with high-risk human cytomegalovirus.

Authors:  Zeina Nehme; Sébastien Pasquereau; Sandy Haidar Ahmad; Ranim El Baba; Georges Herbein
Journal:  EBioMedicine       Date:  2022-05-18       Impact factor: 11.205

4.  Chromatin Memory in the Development of Human Cancers.

Authors:  Yixin Yao; Thomas L Des Marais; Max Costa
Journal:  Gene Technol       Date:  2014-08-11

5.  Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation.

Authors:  Relja Popovic; Eva Martinez-Garcia; Eugenia G Giannopoulou; Quanwei Zhang; Qingyang Zhang; Teresa Ezponda; Mrinal Y Shah; Yupeng Zheng; Christine M Will; Eliza C Small; Youjia Hua; Marinka Bulic; Yanwen Jiang; Matteo Carrara; Raffaele A Calogero; William L Kath; Neil L Kelleher; Ji-Ping Wang; Olivier Elemento; Jonathan D Licht
Journal:  PLoS Genet       Date:  2014-09-04       Impact factor: 5.917

6.  Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth.

Authors:  Franco Izzo; Florencia Mercogliano; Leandro Venturutti; Mercedes Tkach; Gloria Inurrigarro; Roxana Schillaci; Leandro Cerchietti; Patricia V Elizalde; Cecilia J Proietti
Journal:  Breast Cancer Res       Date:  2014-12-06       Impact factor: 6.466

7.  Genetic alterations of histone lysine methyltransferases and their significance in breast cancer.

Authors:  Lanxin Liu; Sarah Kimball; Hui Liu; Andreana Holowatyj; Zeng-Quan Yang
Journal:  Oncotarget       Date:  2015-02-10

8.  Shift in GATA3 functions, and GATA3 mutations, control progression and clinical presentation in breast cancer.

Authors:  Helit Cohen; Rotem Ben-Hamo; Moriah Gidoni; Ilana Yitzhaki; Renana Kozol; Alona Zilberberg; Sol Efroni
Journal:  Breast Cancer Res       Date:  2014-11-20       Impact factor: 6.466

9.  Genotranscriptomic meta-analysis of the Polycomb gene CBX2 in human cancers: initial evidence of an oncogenic role.

Authors:  P-L Clermont; L Sun; F Crea; K L Thu; A Zhang; A Parolia; W L Lam; C D Helgason
Journal:  Br J Cancer       Date:  2014-09-16       Impact factor: 7.640

10.  EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features.

Authors:  Shuangping Guo; Xia Li; Joseph Rohr; Yingmei Wang; Shirong Ma; Peng Chen; Zhe Wang
Journal:  Diagn Pathol       Date:  2016-04-26       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.